Omega-3 fatty acid supplementation and cardiovascular disease events - Reply

JAMA

Volumn 309, Issue 1, 2013, Pages 29-

  Rizos, Evangelos C ^a   Ntzani, Evangelia E ^b   Elisaf, Moses S ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DRUG TISSUE LEVEL; HUMAN; LETTER; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 84871798398     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.116657     Document Type: Letter

References (5)

1. Reiner Z, Catapano AL, De Backer G, et al; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-1818.
2. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W64.
3. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0 [updated March 2011]. http://www.cochrane-handbook. org. Accessibility verified December 5, 2012.
4. Bender R, Bunce C, Clarke M, et al. Attention should be given to multiplicity issues in systematic reviews. J Clin Epidemiol. 2008;61(9):857-865.
5. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Introduction. http://www.gissi.org/Egissip/T-Intro.php. Accessed November 12, 2012.